As filed with the Securities and Exchange Commission on October 30, 2001
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 8731 | 94-3248524 |
(State of Incorporation) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification No.) |
240 East Grand Avenue
South San Francisco, California 94080
(650) 624-1100
(Address of principal executive offices)
2001 Non-Officer Equity Incentive Plan
(Full title of the plan)
James M. Gower
Chairman of the Board and Chief Executive Officer
Rigel Pharmaceuticals, Inc.
240 East Grand Avenue
South San Francisco, California 94080
(650) 624-1100
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Robert L. Jones, Esq.
Suzanne Sawochka Hooper, Esq.
Cooley Godward LLP
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306
(650) 843-5000
CALCULATION OF REGISTRATION FEE
Title of Securities to be Registered |
Amount to be Registered |
Proposed Maximum Offering Price Per Share (1) |
Proposed Maximum Aggregate Offering Price (1) |
Amount of Registration Fee |
||||
Stock Options and Common Stock (par value $.001) |
3,500,000 shares | $5.55-$5.77 | $19,485,912.50 | $4,871.48 | ||||
The chart below illustrates the calculation of the registration fee:
Securities | Number of Shares | Offering Price Per Share(1) |
Aggregate Offering Price |
|||
Shares issuable pursuant to outstanding stock options under the 2001 Non-Officer Equity Incentive Plan | 276,875 | $5.77 | $1,597,568.75 | |||
Shares issuable pursuant to unissued stock options under the 2001 Non-Officer Equity Incentive Plan | 3,223,125 | $5.55 | $17,888,343.75 | |||
Proposed Maximum Offering Price | $19,485,912.50 | |||||
Registration Fee | $4,871.48 | |||||
Approximate date of commencement of proposed sale to the public:
As soon as practicable after this Registration Statement becomes effective.
Item 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed by Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") with the Securities and Exchange Commission are incorporated by reference into this Registration Statement:
(a) The Company's Annual Report on Form 10-K, filed pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), for the fiscal year ended December 31, 2000;
(b) The Company's Quarterly Reports on Form 10-Q, filed pursuant to Section 13 of the Exchange Act, for the quarters ended March 31 and June 30, 2001; and
(c) The description of the Company's Common Stock that is contained in the Registration Statement on Form 8-A, filed on October 3, 2000 pursuant to Section 12 of the Exchange Act, including any amendment or report filed for the purpose of updating such description.
All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents.
Item 4. DESCRIPTION OF SECURITIES
Not applicable.
Item 5. INTERESTS OF NAMED EXPERTS AND COUNSEL
The validity of the common stock offered under this prospectus will be passed upon for the Company by Cooley Godward LLP, Palo Alto, California.
Item 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS
As permitted by Delaware law, Rigel's amended and restated certificate of incorporation provides that no director will be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:
Our amended and restated certificate of incorporation further provides that we must indemnify our directors and executive officers and may indemnify our other officers and employees and agents to the fullest extent permitted by Delaware law. We believe that indemnification under our amended and restated certificate of incorporation covers negligence and gross negligence on the part of indemnified parties.
We have entered into indemnification agreements with each of our directors and certain officers. These agreements, among other things, require us to indemnify each director and officer for certain expenses including attorneys' fees, judgements, fines and settlement amounts incurred by any such person in any action or proceeding, including any action by or in the right of Rigel, arising out to he person's services as our director or officer, any subsidiary of ours or any other company or enterprise to which the person provides services at our request.
Item 7. EXEMPTION FROM REGISTRATION CLAIMED
Not applicable.
Exhibit Number |
|
|
---|---|---|
4.1* | Amended and Restated Certificate of Incorporation of the Company. | |
4.2* |
Amended and Restated Bylaws of the Company. |
|
4.3* |
Specimen Common Stock Certificate. |
|
5.1 |
Opinion of Cooley Godward LLP. |
|
23.1 |
Consent of Ernst & Young LLP, Independent Auditors. |
|
23.3 |
Consent of Cooley Godward LLP. Reference is made to Exhibit 5.1. |
|
24.1 |
Power of Attorney is contained on the signature pages to this Registration Statement. |
|
99.1 |
2001 Non-Officer Equity Incentive Plan. |
|
99.2 |
Form of Stock Option Agreement pursuant to the 2001 Non-Officer Equity Incentive Plan. |
(a) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the issuer pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference herein.
(b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on October 30, 2001.
RIGEL PHARMACEUTICALS, INC. | ||||
By |
/s/ James M. Gower James M. Gower Chairman of the Board and Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints James M. Gower and Brian C. Cunningham, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date |
||
---|---|---|---|---|
/s/ James M. Gower James M. Gower |
Chairman of the Board and Chief Executive Officer (Principal Executive Officer) |
October 30, 2001 | ||
/s/ James H. Welch James H. Welch |
Vice President, Chief Financial Officer and Secretary (Principal Financial and Accounting Officer) |
October 30, 2001 |
||
/s/ Donald G. Payan Donald G. Payan |
Executive Vice President, Chief Scientific Officer and Director |
October 30, 2001 |
||
/s/ Jean Deleage Jean Deleage |
Director |
October 30, 2001 |
||
/s/ Alan D. Frazier Alan D. Frazier |
Director |
October 30, 2001 |
/s/ Walter H. Moos Walter H. Moos |
Director |
October 30, 2001 |
||
/s/ Stephen A. Sherwin Stephen A. Sherwin |
Director |
October 30, 2001 |
||
/s/ Thomas S. Volpe Thomas S. Volpe |
Director |
October 30, 2001 |
Exhibit Number |
Description |
Sequential Page Number |
||
---|---|---|---|---|
4.1* | Amended and Restated Certificate of Incorporation of the Company. | |||
4.2* |
Amended and Restated Bylaws of the Company. |
|||
4.3* |
Specimen Common Stock Certificate. |
|||
5.1 |
Opinion of Cooley Godward LLP. |
|||
23.1 |
Consent of Ernst & Young LLP, Independent Auditors. |
|||
23.3 |
Consent of Cooley Godward LLP. Reference is made to Exhibit 5.1. |
|||
24.1 |
Power of Attorney is contained on the signature pages to this Registration Statement. |
|||
99.1 |
2001 Non-Officer Equity Incentive Plan. |
|||
99.2 |
Form of Stock Option Agreement pursuant to the 2001 Non-Officer Equity Incentive Plan. |